GtoPdb Ligand ID: 7984

Synonyms: 17-1A | PANOREX® (proposed trade name)
Compound class: Antibody
Comment: Edrecolomab is directed against epithelial cell adhesion molecule (EPCAM; UniProt accession P16422).
No information available.
Summary of Clinical Use
Edrecolomab was developed as a treatment for colon cancer with a Phase II study (NCT00002968) being completed. The antibody was approved in Germany (1995) for this indication. The antibody shows little benefit over other therapies for colon cancer, and future development effort is focussing on other types of cancer.
Mechanism Of Action and Pharmacodynamic Effects
Edrecolomab acts by binding to EPCAM on malignant cells (EpCAM), and this attracts immune cells which destroy the malignant cells.